go to medicines.ie homepage
Font Size
Search for:  
select
  Advanced Search

Cephalon Pharma (Ireland) Ltd
Suite 43, Northwood Court, Northwood Business Campus, Santry, Dublin 9,
Telephone: +353 1 8621600
Fax: +353 1 8621601
Medical Information e-mail: UKMedInfo@cephalon.com
Summary of Product Characteristics last updated on medicines.ie: 06/04/2010
SPC Targretin Capsules

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 06/04/2010 and displayed until Current
Reasons for adding or updating:
  • Change to MA holder contact details
Date of revision of text on the SPC:   30-Apr-2009
Legal Category:   Product subject to restricted prescription (C)

Free-text change information supplied by the pharmaceutical company
Change in MAH address section 7
Updated on 03/10/2006 and displayed until 06/04/2010
Reasons for adding or updating:
  • Change to section 6.3 - Shelf life
  • Change to section 9 - Date of renewal of authorisation
Date of revision of text on the SPC:   08/2006
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company
Shelf life increased during renewal process
Updated on 18/07/2006 and displayed until 03/10/2006
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
Date of revision of text on the SPC:   04/2006
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company
  1. NAME OF THE MEDICINAL PRODUCT  Targretin 75 mg soft capsules
 
4.1 Therapeutic indications Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.
 
 4.8 Undesirable effects - completely updated with additional safety data submitted as part of the renewal process
Updated on 04/07/2003 and displayed until 18/07/2006
Reasons for adding or updating:
  • New SPC for medicines.ie

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
  Bexarotene